Prenetics Global Limited (PRE) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Analysis Summary
Prenetics Global Limited reported revenue of $92.4M in the most recent fiscal year, growing at a 5-year CAGR of 7.2%.
Trailing-twelve-month margins: gross margin 62.6%, operating margin -35.2%, net margin -47.4%.
At the current price of $24.19, PRE has negative trailing earnings (P/E not meaningful) and an ROE of -49.17%. Market capitalisation stands at $411M.
Balance sheet quality for PRE: current ratio of 3.0, net cash position of $59.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $24.19 |
| Market Cap | $411M |
| Exchange | NASDAQ |
| Country | HK |
Valuation Ratios
| Price / Book | 4.43 |
| EV / EBITDA | -5.98 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -49.17% |
| Return on Invested Capital | -42.66% |
| Return on Assets | -44.00% |
| Gross Margin | 62.61% |
| Operating Margin | -35.20% |
| Net Margin | -47.43% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 4.04 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRE | Prenetics Global Limited | $411M | 4.43 | -49.2% | |
| TMO | Thermo Fisher Scientific Inc. | $244.6B | 36.71 | 4.81 | 13.4% |
| 0R0H.L | Thermo Fisher Scientific Inc. | $244.6B | 35.47 | 4.45 | 12.6% |
| 0R2B.L | Danaher Corporation | $150.1B | |||
| DHR | Danaher Corporation | $149.3B | 39.34 | 2.98 | 7.7% |
| NTRA | Natera, Inc. | $52.5B | 30.51 | -11.7% | |
| 0HAV.L | Agilent Technologies, Inc. | $49.8B | 30.76 | 6.00 | 20.5% |
| 0JDM.L | IQVIA Holdings Inc. | $45.7B |
Price Performance
| 1 month | +17.38% |
| 3 months | +7.41% |
| Year-to-date | +39.81% |
| 1 year | +103.14% |
| 3 years | +202.06% |
52-Week Range
| 52-week High | $27.24 |
| 52-week Low | $9.28 |
| Avg Volume (90d) | 240K |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2016-02-17 | $0.0602 | 1.00% |
| 2015-11-04 | $0.0602 | 1.00% |
| 2015-08-05 | $0.0602 | 1.00% |
| 2015-05-06 | $0.0602 | 1.00% |
| 2015-02-11 | $0.0602 | 1.00% |
| 2014-11-18 | $0.0576 | 0.95% |
| 2014-08-14 | $0.0576 | 0.95% |
| 2014-05-15 | $0.0576 | 0.95% |
| 2014-02-13 | $0.0576 | 0.95% |
| 2013-11-14 | $0.0550 | 0.91% |
Related companies: ARMP · ATLN · CDXS · IMDX · MXCT · OSUR · PROF
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of PRE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks